BiovaxID mantle cell lymphoma trial data to be presented in June
Biovest International, makers of the personalized therapeutic lymphoma vaccine BiovaxID, have announced that data from the company's Phase II mantle cell lymphoma clinical trial will be presented by the National Cancer Institute at the upcoming 2012 American Society of Clinical Oncology Annual Meeting in June (ASCO 2012).
The Phase II trial was also conducted by researchers at the National Cancer Institute.
The presentation's abstract is titled "Association of idiotype vaccine-induced T-cell response with improved survival and time-to-next treatment (TTNT) in untreated mantle cell lymphoma (MCL)" and will be presented by the NCI on Saturday, June 2nd at McCormick Place in Chicago.
"We continue to be very proud of the NCI's long-term commitment to the development of this important personalized cancer vaccine," stated Biovest's President & CEO, Samuel S. Duffey, Esq. "We look forward to commenting on this new BiovaxID clinical trial data when ASCO lifts the embargo."
Source: MarketWatch
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
